title: [Safety and Efficacy of Etanercept in Rheumatoid Arthritis With End-stage Chronic Renal Failure].
abstract: The use of etanercept in rheumatoid arthritis patients with end-stage renal failure has not been well reported. We report here the case of 58-years-old patient who was treated with 50 mg of etanercept once a week to control the activity of her disease. The patient improved after starting the treatement. No serious infectious complication or side effects were seen. The follow-up was 18 months. Our case showed the safety and efficacity of etanercept rheumatoid arthritis in patient with end-stage renal failure.
authors.forename: Ines
authors.initials: I
authors.lastname: Mahmoud
authors.forename: Leila
authors.initials: L
authors.lastname: Gafsi
authors.forename: Rawdha
authors.initials: R
authors.lastname: Tekaya
authors.forename: Olfa
authors.initials: O
authors.lastname: Saidane
authors.forename: Hana
authors.initials: H
authors.lastname: Sahli
authors.forename: Leila
authors.initials: L
authors.lastname: Abdelmoula
authors.forename: Rafik
authors.initials: R
authors.lastname: Zouari
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept